{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:45Z","timestamp":1792417425860,"version":"4.4.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myasthenia gravis (MG) is a prototypical antibody-mediated autoimmune disorder of the neuromuscular junction, characterized by fluctuating skeletal muscle weakness and substantial morbidity. Although therapeutic advances have markedly improved survival and long-term outcomes, MG is not a gender-homogeneous condition. Women are disproportionately affected, exhibit a distinct bimodal age distribution, and experience the disease within unique biological and psychosocial contexts that shape presentation, disease course, quality of life, and treatment response. Accumulating evidence highlights sex-specific differences in immune reactivity, hormonal influences, thymic pathology, clinical severity, fatigue burden, and patient-reported outcomes. Notably, women consistently report poorer quality of life despite comparable disease severity. Reproductive health introduces additional complexity, as pregnancy planning, contraception, teratogenic risk, postpartum exacerbation, and neonatal complications profoundly influence clinical decision-making and patient autonomy. Despite these well-recognized disparities, sex-specific considerations remain insufficiently integrated into routine care and are strikingly underrepresented in clinical trial design. Most MG trials fail to stratify outcomes by sex, account for sex-dependent pharmacokinetics or pharmacodynamics, or include pregnancy-relevant populations, resulting in critical evidence gaps. This narrative review synthesizes current knowledge on gender-related pathophysiological mechanisms, clinical phenotypes, and life stage\u2013specific management of MG, with particular emphasis on the reproductive years. It also briefly examines the evolving role of novel biological therapies, including complement inhibitors, neonatal Fc receptor inhibitors, and B-cell\u2013directed agents, which offer promise for more targeted and potentially safer treatment paradigms. Systematic gender-stratified analyses, dedicated pregnancy registries, and proactive, physician-led counselling are essential to advancing equitable, evidence-based care for women living with MG.<\/jats:p>","DOI":"10.4103\/aian.aian_13_26","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:00:15Z","timestamp":1780506015000},"page":"327-335","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Women and Myasthenia Gravis"],"prefix":"10.4103","volume":"29","author":[{"given":"Deepak","family":"Menon","sequence":"first","affiliation":[{"name":"Department of Neurology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seena","family":"Vengalil","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraswati","family":"Nashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atchayaram","family":"Nalini","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"R1-20261019","doi-asserted-by":"crossref","first-page":"111793","DOI":"10.1016\/j.mad.2023.111793","article-title":"Sex differences in neuromuscular disorders","volume":"211","author":"Vinciguerra","year":"2023","journal-title":"Mech Ageing Dev"},{"key":"R2-20261019","doi-asserted-by":"crossref","first-page":"17562864251344742","DOI":"10.1177\/17562864251344742","article-title":"Female gender and quality of life outcomes in myasthenia gravis: A systematic review and meta-analysis","volume":"18","author":"Beeching","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"R3-20261019","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3389\/fimmu.2018.02279","article-title":"Sex hormones in acquired immunity and autoimmune disease","volume":"9","author":"Moulton","year":"2018","journal-title":"Front Immunol"},{"key":"R4-20261019","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"Ngo","year":"2014","journal-title":"Front Neuroendocrinol"},{"key":"R5-20261019","doi-asserted-by":"crossref","first-page":"600","DOI":"10.2353\/ajpath.2008.071008","article-title":"Sex differences in autoimmune disease from a pathological perspective","volume":"173","author":"Fairweather","year":"2008","journal-title":"Am J Pathol"},{"key":"R6-20261019","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0022-510X(98)00031-8","article-title":"Exacerbation of myasthenia gravis during the menstrual period","volume":"156","author":"Leker","year":"1998","journal-title":"J Neurol Sci"},{"key":"R7-20261019","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1753495X211041899","article-title":"Myasthenia gravis in pregnancy: Systematic review and case series","volume":"15","author":"Banner","year":"2022","journal-title":"Obstet Med"},{"key":"R8-20261019","first-page":"767","article-title":"Myasthenia gravis and pregnancy: Toronto specialty center experience","volume":"48","author":"Alharbi","year":"2021","journal-title":"Can J Neurol Sci"},{"key":"R9-20261019","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/WNL.0000000000003339","article-title":"Increased risk for clinical onset of myasthenia gravis during the postpartum period","volume":"87","author":"Boldingh","year":"2016","journal-title":"Neurology"},{"key":"R10-20261019","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nmd.2017.01.021","article-title":"Clinical follow-up of pregnancy in myasthenia gravis patients","volume":"27","author":"Ducci","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"R11-20261019","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"R12-20261019","doi-asserted-by":"crossref","first-page":"790941","DOI":"10.3389\/fneur.2021.790941","article-title":"Comorbid autoimmune diseases in patients with myasthenia gravis: A retrospective cross-sectional study of a Chinese cohort","volume":"12","author":"Shi","year":"2021","journal-title":"Front Neurol"},{"key":"R13-20261019","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: An update","volume":"10","author":"Sheikh","year":"2021","journal-title":"J Clin Med"},{"key":"R14-20261019","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/d41586-024-00267-6","article-title":"Why autoimmune disease is more common in women: X chromosome holds clues","volume":"626","author":"Dolgin","year":"2024","journal-title":"Nature"},{"key":"R15-20261019","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/genes13040696","article-title":"Preferential X chromosome inactivation as a mechanism to explain female preponderance in myasthenia gravis","volume":"13","author":"Nicol\u00ec","year":"2022","journal-title":"Genes (Basel)"},{"key":"R16-20261019","doi-asserted-by":"crossref","first-page":"e1594","DOI":"10.1212\/WNL.0000000000207642","article-title":"Clinical characteristics associated with secondary generalization in patients with ocular myasthenia gravis","volume":"101","author":"Fang","year":"2023","journal-title":"Neurology"},{"key":"R17-20261019","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12016-016-8558-3","article-title":"Thymic germinal centers and corticosteroids in myasthenia gravis: An immunopathological study in 1035 cases and a critical review","volume":"52","author":"Truffault","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R18-20261019","doi-asserted-by":"crossref","first-page":"e70114","DOI":"10.1111\/ene.70114","article-title":"Differences between females and males in the diagnostic delay and clinical course of thymectomised myasthenia gravis","volume":"32","author":"Myllynen","year":"2025","journal-title":"Eur J Neurol"},{"key":"R19-20261019","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/mus.27331","article-title":"Gender differences in clinical outcomes in myasthenia gravis: A prospective cohort study","volume":"64","author":"Thomsen","year":"2021","journal-title":"Muscle Nerve"},{"key":"R20-20261019","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26104","article-title":"Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry","author":"Lee","year":"2018","journal-title":"Muscle Nerve"},{"key":"R21-20261019","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.27397","article-title":"What is the significance of gender difference in myasthenia gravis?","volume":"64","author":"Gable","year":"2021","journal-title":"Muscle Nerve"},{"key":"R22-20261019","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","article-title":"Fatigue in patients with myasthenia gravis. A systematic review of the literature","volume":"30","author":"Ruiter","year":"2020","journal-title":"Neuromuscular Disord"},{"key":"R23-20261019","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fneur.2018.00077","article-title":"Clinical characteristics of juvenile myasthenia gravis in southern China","volume":"9","author":"Huang","year":"2018","journal-title":"Front Neurol"},{"key":"R24-20261019","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/mus.24556","article-title":"Impact of myasthenia gravis on family planning: How do women with myasthenia gravis decide and why?","volume":"52","author":"Ohlraun","year":"2015","journal-title":"Muscle Nerve"},{"key":"R25-20261019","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ard.2025.06.242","article-title":"POS0887 Perception of women of reproductive age group with autoimmune diseases on sexual and reproductive health: A PAN India questionnaire-based study","volume":"84","author":"Shah","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R26-20261019","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13023-022-02205-z","article-title":"Risk factors for pregnancy-related clinical outcome in myasthenia gravis: A systemic review and meta-analysis","volume":"17","author":"Su","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"R27-20261019","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"R28-20261019","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: Immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R29-20261019","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","article-title":"Myasthenia in pregnancy: Best practice guidelines from a UK multispecialty working group","volume":"85","author":"Norwood","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R30-20261019","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.pedneo.2021.05.020","article-title":"Clinical and pathophysiologic relevance of autoantibodies in neonatal myasthenia gravis","volume":"62","author":"Iijima","year":"2021","journal-title":"Pediat Neonatol"},{"key":"R31-20261019","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jcpt.12672","article-title":"Tacrolimus interaction with oral oestrogen in kidney transplant recipients: A case-control study","volume":"43","author":"Ghadimi","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"R32-20261019","first-page":"713","article-title":"The new pregnancy and lactation labeling rule","volume":"41","author":"Pernia","year":"2016","journal-title":"P T"},{"key":"R33-20261019","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ncl.2018.09.003","article-title":"Management of myasthenia gravis in pregnancy","volume":"37","author":"Waters","year":"2019","journal-title":"Neurol Clin"},{"key":"R34-20261019","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.rdc.2017.04.013","article-title":"A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes","volume":"43","author":"Bandoli","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"R35-20261019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00508-019-1448-y","article-title":"Immunosuppressives and biologics during pregnancy and lactation","volume":"131","author":"Puchner","year":"2019","journal-title":"Wien Klin Wochenschr"},{"key":"R36-20261019","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ibd.22948","article-title":"Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease","volume":"19","author":"Akbari","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R37-20261019","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jcpt.13340","article-title":"Pregnancy outcomes in female patients exposed to cyclosporin-based versus tacrolimus-based immunosuppressive regimens after liver\/kidney transplantation: A systematic review and meta-analysis","volume":"46","author":"Gong","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"R38-20261019","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00007890-200104270-00006","article-title":"Pregnancy outcome after cyclosporine therapy during pregnancy: A meta-analysis","volume":"71","author":"Bar Oz","year":"2001","journal-title":"Transplantation"},{"key":"R39-20261019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejogrb.2021.02.027","article-title":"Therapeutic plasma exchange in pregnancy: A literature review","volume":"260","author":"Wind","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R40-20261019","first-page":"e42772","article-title":"Choices and challenges with treatment of myasthenia gravis in pregnancy: A systematic review","volume":"15","author":"Kumar","year":"2023","journal-title":"Cureus"},{"key":"R41-20261019","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/pn-2022-003426","article-title":"Anti-CD20 therapies in pregnancy and breast feeding: A review and ABN guidelines","volume":"23","author":"Dobson","year":"2023","journal-title":"Pract Neurol"},{"key":"R42-20261019","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14728214.2021.1952982","article-title":"Emerging drugs for the treatment of myasthenia gravis","volume":"26","author":"Menon","year":"2021","journal-title":"Expert Opin Emerg Drugs"},{"key":"R43-20261019","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3389\/fneur.2020.00538","article-title":"Novel treatments in myasthenia gravis","volume":"11","author":"Menon","year":"2020","journal-title":"Front Neurol"},{"key":"R44-20261019","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"R45-20261019","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for the use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R46-20261019","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1017\/cjn.2021.56","article-title":"Practical aspects of transitioning from intravenous to subcutaneous immunoglobulin therapy in neuromuscular disorders","volume":"49","author":"Menon","year":"2022","journal-title":"Can J Neurol Sci"},{"key":"R47-20261019","doi-asserted-by":"crossref","first-page":"e209722","DOI":"10.1212\/WNL.0000000000209722","article-title":"Effect of immunosuppression in risk of developing generalized symptoms in ocular myasthenia gravis","volume":"103","author":"Menon","year":"2024","journal-title":"Neurology"},{"key":"R48-20261019","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.c.31723","article-title":"Fetal arthrogryposis: Challenges and perspectives for prenatal detection and management","volume":"181","author":"Filges","year":"2019","journal-title":"Am J Med Genet"},{"key":"R49-20261019","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1093\/brain\/awad153","article-title":"The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD)","volume":"146","author":"Allen","year":"2023","journal-title":"Brain"},{"key":"R50-20261019","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1212\/NXI.0000000000000057","article-title":"Fetal acetylcholine receptor inactivation syndrome","volume":"2","author":"Hacohen","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R51-20261019","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/mus.27369","article-title":"Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis","volume":"64","author":"Vijayan","year":"2021","journal-title":"Muscle Nerve"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_13_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:05:37Z","timestamp":1792415137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_13_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_13_26","relation":{},"ISSN":["0972-2327","1998-3549"],"issn-type":[{"value":"0972-2327","type":"print"},{"value":"1998-3549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2026-01-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}